Veraxa Biotech is trading at $1.10, up 6.80% in pre-market, with no confirmed company-specific catalyst identified.
- This compares with the November 2 close of $1.03.
- The investor-relations page lists October 13 as the latest release; the October 30 human-relevant testing update is prior news, not a confirmed explanation for the rise.
- Broader index indications are mixed and modest, and no reliable pre-market volume details were established.